Celon Pharma Future Growth
Future criteria checks 1/6
Celon Pharma is forecast to grow earnings and revenue by 14.4% and 3.2% per annum respectively. EPS is expected to decline by 17.8% per annum. Return on equity is forecast to be -0.4% in 3 years.
Key information
14.4%
Earnings growth rate
-17.8%
EPS growth rate
| Pharmaceuticals earnings growth | 21.2% |
| Revenue growth rate | 3.2% |
| Future return on equity | -0.4% |
| Analyst coverage | Low |
| Last updated | 21 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 273 | 5 | 28 | 57 | 4 |
| 12/31/2025 | 328 | 51 | 16 | 90 | 4 |
| 12/31/2024 | 232 | -20 | 29 | 23 | 4 |
| 9/30/2024 | 280 | 19 | -33 | -17 | N/A |
| 6/30/2024 | 207 | -45 | -12 | 6 | N/A |
| 3/31/2024 | 209 | -34 | -23 | 2 | N/A |
| 12/31/2023 | 214 | -28 | -41 | -8 | N/A |
| 9/30/2023 | 214 | -25 | -31 | 7 | N/A |
| 6/30/2023 | 211 | -30 | -53 | -16 | N/A |
| 3/31/2023 | 196 | -47 | -42 | -8 | N/A |
| 12/31/2022 | 194 | -39 | -39 | -5 | N/A |
| 9/30/2022 | 191 | -31 | -39 | -10 | N/A |
| 6/30/2022 | 186 | -28 | -11 | 32 | N/A |
| 3/31/2022 | 191 | -17 | -17 | 25 | N/A |
| 12/31/2021 | 196 | -12 | 3 | 44 | N/A |
| 9/30/2021 | 186 | -11 | 7 | 60 | N/A |
| 6/30/2021 | 185 | -2 | 3 | 57 | N/A |
| 3/31/2021 | 170 | 0 | -18 | 71 | N/A |
| 12/31/2020 | 157 | -1 | -28 | 72 | N/A |
| 9/30/2020 | 142 | 4 | -58 | 37 | N/A |
| 6/30/2020 | 128 | 5 | -88 | 6 | N/A |
| 3/31/2020 | 109 | 3 | -85 | -19 | N/A |
| 12/31/2019 | 102 | 12 | -70 | -5 | N/A |
| 9/30/2019 | 110 | 17 | -69 | 6 | N/A |
| 6/30/2019 | 118 | 23 | -61 | 15 | N/A |
| 3/31/2019 | 124 | 29 | -31 | 37 | N/A |
| 12/31/2018 | 125 | 30 | -39 | 28 | N/A |
| 9/30/2018 | 116 | 30 | -30 | 27 | N/A |
| 6/30/2018 | 109 | 26 | N/A | 34 | N/A |
| 3/31/2018 | 107 | 28 | N/A | 26 | N/A |
| 12/31/2017 | 107 | 26 | N/A | 25 | N/A |
| 9/30/2017 | 129 | 22 | N/A | 18 | N/A |
| 6/30/2017 | 127 | 24 | N/A | 23 | N/A |
| 3/31/2017 | 115 | 27 | N/A | 28 | N/A |
| 12/31/2016 | 129 | 38 | N/A | 21 | N/A |
| 9/30/2016 | 111 | 42 | N/A | 34 | N/A |
| 12/31/2015 | 108 | 37 | N/A | 52 | N/A |
| 12/31/2014 | 98 | 52 | N/A | 24 | N/A |
| 12/31/2013 | 72 | 18 | N/A | 8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8RP's forecast earnings growth (14.4% per year) is above the savings rate (1%).
Earnings vs Market: 8RP's earnings (14.4% per year) are forecast to grow slower than the German market (21% per year).
High Growth Earnings: 8RP's earnings are forecast to grow, but not significantly.
Revenue vs Market: 8RP's revenue (3.2% per year) is forecast to grow slower than the German market (5.6% per year).
High Growth Revenue: 8RP's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 8RP is forecast to be unprofitable in 3 years.